Links

03/12/2025

ID6294: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)

14/11/2025

ID6470: Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy

14/11/2025

ID6415: Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency

31/10/2025

ID5082: Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments

31/10/2025

TA1102: Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)

30/10/2025

ID6378: Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer (review of TA721)

15/11/2023

ID4031: Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer

27/04/2023

Assessments in progress

15/07/2022

Image links

08/01/2022

Homepage block

07/01/2022

Appraisals in progress (3)

07/01/2022

standalones

08/11/2021

Appraisals in progress

08/11/2021

Appraisals in progress (1)

12/07/2021

WNPU

08/07/2021

YCC Wales useful links

28/06/2021

homepage links

28/06/2021

YCC Wales social links

25/06/2021

YCC Wales contact email

18/06/2021

Latest One Wales decisions